SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-051775
Filing Date
2024-02-29
Accepted
2024-02-29 07:15:54
Documents
16
Period of Report
2024-02-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d778379d8k.htm   iXBRL 8-K 26016
2 EX-99.1 d778379dex991.htm EX-99.1 55091
6 GRAPHIC g778379snap2.jpg GRAPHIC 1733
  Complete submission text file 0001193125-24-051775.txt   214351

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akro-20240229.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20240229_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20240229_pre.xml EX-101.PRE 11261
17 EXTRACTED XBRL INSTANCE DOCUMENT d778379d8k_htm.xml XML 3653
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 24698821
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)